PM: More than half a million people in the UK have received Covid-19 vaccine

·6-min read

More than half a million people in the UK have been vaccinated against Covid-19, Boris Johnson said.

The Prime Minister told a Downing Street press conference more than 500,000 people in the UK have now received their first dose of the two-part vaccine since British grandmother Margaret Keenan became the first patient in the world on December 8 to receive the Pfizer Covid-19 jab following its clinical approval.

Afterwards, Health Secretary Matt Hancock said in a tweet it was “such good news”.

As the nation is faced with a fast-spreading new variant of the virus, a Kent resident suggested the vaccine rollout might now be expanded to cover different geographical areas and working age people.

Mr Johnson said the Committee on Immunisation and Vaccination is “sticking” to its priority list which currently focuses on giving the vaccine to the 80-plus age group, the particularly vulnerable and those in care homes.

He described it as “the sensible thing to do” while the Government’s chief scientific adviser Sir Patrick Vallance said the two-part vaccine should still be effective against the new rapidly-transmitted Covid variant strain.

Sir Patrick told the Downing Street press conference: “The transmission is increased, we can’t say exactly by how much, but it is clearly substantially increased, so it is more transmissible, which is why we see it growing so fast and spreading to so many areas.

“There is no evidence that the disease course is any different, so if you catch it the disease looks the same as any other form of Covid infection.

“In terms of the immune response, there is nothing to suggest that this won’t have the same susceptibility to antibody attack from vaccine or pre-existing infection as any other form.”

Sir Patrick added the vaccine “looks as though it should be as effective and that’s obviously being looked at”.

To view this content, you'll need to update your privacy settings.
Please click here to do so.

It comes as an expert warned vaccination alone will not be enough to bring coronavirus in the community down to “very low levels”, and social restrictions may have to continue until around 50% of the population has been vaccinated.

Many people have been hoping for a return to normality once the elderly and those most at risk from Covid-19 have received the jab.

But scientists say this might not be enough to see an end to measures such as social distancing and wearing face masks.

They suggest restrictions may be needed until at least half of the UK’s population has been vaccinated.

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said vaccination alone will not be enough to bring the virus circulating in the community to “very low levels”.

Speaking at a Science and Media Centre press briefing, he said: “We actually need to have the absolute amount of virus circulating to be very low.

“And we won’t do that by vaccination alone until we’re getting 50% of the population vaccinated or more, and that’s going to be quite a bit of a long way off yet.

Margaret Keenan, 90, was the first patient to receive the Pfizer/BioNtech Covid-19 vaccine (Jacob King/PA)
Margaret Keenan, 90, was the first patient to receive the Pfizer/BioNtech Covid-19 vaccine (Jacob King/PA)

“So I fear that the sort of restrictions we have, the non-medical interventions, are going to need to be carried on.”

Prof Evans added: “I think if people take these seriously, then it’s possible for various economic activities to go ahead, but you have to make sure that you are keeping to the non-medical interventions, being aware and behaving as if every person you contact has got the virus.

“And that you have it as well.

“And when you behave in a way that realises that, and that the consequences for either you or the person around you getting the virus can be very serious, then it changes people’s behaviour.

“And we’re going to have to go on doing that for quite a long time.”

Health Secretary Matt Hancock has said that, as of 8am on Saturday morning, 350,000 people had been vaccinated.

Adam Finn, professor of paediatrics at the University of Bristol, also said that even if the elderly are vaccinated, social restrictions may have to continue for some time.

How the Pfizer/BioNTech vaccine works
(PA Graphics)

He explained: “I think the modelling is very clear that, even if you had high coverage and high levels of protection in the high-risk groups, you would still see epidemics, and large numbers of hospitalisations and deaths if you relax the measures before you have a broader control of viral circulation in the population at large.

“So I think the idea that you can immunise a large proportion of the elderly and then kind of go back to normal is misguided.

“I think that none of the models suggest that that’s going to be possible.”

Peter Openshaw, professor of experimental medicine at Imperial College London, explained that as well as the elderly, there has to be concern about the effects of long Covid in relatively young people.

He said he found the idea of his colleagues or his relatives becoming affected by long Covid “terrifying”.

Prof Openshaw added: “We shouldn’t stop vaccinating once we have just vaccinated the high risk.

“I think we have to get the population vaccinated and I think the prospects of vaccines preventing long Covid are quite good.”

The experts said it is not yet possible to say how much of the population needs to be vaccinated to achieve herd immunity.

They explained that, while there is insufficient evidence on how effective the vaccines are at reducing transmission, the Pfizer-BioNTech and Moderna jabs have demonstrated such high efficacy, it would be surprising if there was no impact on transmission.

Prof Openshaw said his concern was the hard to reach in the community, people who are very doubtful about vaccines or those not very well informed.

He said this is something that needs to be focused on.

He added that the efficacy of the Oxford-AstraZeneca vaccine, which is yet to receive regulatory approval, against transmission may be “considerable” even if it is not as effective as the other options.

There have been some concerns the Oxford vaccine may not be as good as preventing symptomatic disease as the others, but the experts suggested it would be adequate for very strong population-wide effects if widely deployed.